218 related articles for article (PubMed ID: 25043604)
21. Characterization of Alisertib (MLN8237), an investigational small-molecule inhibitor of aurora A kinase using novel in vivo pharmacodynamic assays.
Manfredi MG; Ecsedy JA; Chakravarty A; Silverman L; Zhang M; Hoar KM; Stroud SG; Chen W; Shinde V; Huck JJ; Wysong DR; Janowick DA; Hyer ML; Leroy PJ; Gershman RE; Silva MD; Germanos MS; Bolen JB; Claiborne CF; Sells TB
Clin Cancer Res; 2011 Dec; 17(24):7614-24. PubMed ID: 22016509
[TBL] [Abstract][Full Text] [Related]
22. Polo-like kinase 1 is a therapeutic target in high-risk neuroblastoma.
Ackermann S; Goeser F; Schulte JH; Schramm A; Ehemann V; Hero B; Eggert A; Berthold F; Fischer M
Clin Cancer Res; 2011 Feb; 17(4):731-41. PubMed ID: 21169242
[TBL] [Abstract][Full Text] [Related]
23. BI 6727, a Polo-like kinase inhibitor with improved pharmacokinetic profile and broad antitumor activity.
Rudolph D; Steegmaier M; Hoffmann M; Grauert M; Baum A; Quant J; Haslinger C; Garin-Chesa P; Adolf GR
Clin Cancer Res; 2009 May; 15(9):3094-102. PubMed ID: 19383823
[TBL] [Abstract][Full Text] [Related]
24. HER2-positive breast cancer cells resistant to trastuzumab and lapatinib lose reliance upon HER2 and are sensitive to the multitargeted kinase inhibitor sorafenib.
Valabrega G; Capellero S; Cavalloni G; Zaccarello G; Petrelli A; Migliardi G; Milani A; Peraldo-Neia C; Gammaitoni L; Sapino A; Pecchioni C; Moggio A; Giordano S; Aglietta M; Montemurro F
Breast Cancer Res Treat; 2011 Nov; 130(1):29-40. PubMed ID: 21153051
[TBL] [Abstract][Full Text] [Related]
25. Combined gene expression profiling and RNAi screening in clear cell renal cell carcinoma identify PLK1 and other therapeutic kinase targets.
Ding Y; Huang D; Zhang Z; Smith J; Petillo D; Looyenga BD; Feenstra K; Mackeigan JP; Furge KA; Teh BT
Cancer Res; 2011 Aug; 71(15):5225-34. PubMed ID: 21642374
[TBL] [Abstract][Full Text] [Related]
26. Evaluation of Protein Kinase Inhibitors with PLK4 Cross-Over Potential in a Pre-Clinical Model of Cancer.
Suri A; Bailey AW; Tavares MT; Gunosewoyo H; Dyer CP; Grupenmacher AT; Piper DR; Horton RA; Tomita T; Kozikowski AP; Roy SM; Sredni ST
Int J Mol Sci; 2019 Apr; 20(9):. PubMed ID: 31035676
[TBL] [Abstract][Full Text] [Related]
27. FAM46C/TENT5C functions as a tumor suppressor through inhibition of Plk4 activity.
Kazazian K; Haffani Y; Ng D; Lee CMM; Johnston W; Kim M; Xu R; Pacholzyk K; Zih FS; Tan J; Smrke A; Pollett A; Wu HS; Swallow CJ
Commun Biol; 2020 Aug; 3(1):448. PubMed ID: 32807875
[TBL] [Abstract][Full Text] [Related]
28. The histone deacetylase inhibitor abexinostat induces cancer stem cells differentiation in breast cancer with low Xist expression.
Salvador MA; Wicinski J; Cabaud O; Toiron Y; Finetti P; Josselin E; Lelièvre H; Kraus-Berthier L; Depil S; Bertucci F; Collette Y; Birnbaum D; Charafe-Jauffret E; Ginestier C
Clin Cancer Res; 2013 Dec; 19(23):6520-31. PubMed ID: 24141629
[TBL] [Abstract][Full Text] [Related]
29. Anti-breast cancer activity of LFM-A13, a potent inhibitor of Polo-like kinase (PLK).
Uckun FM; Dibirdik I; Qazi S; Vassilev A; Ma H; Mao C; Benyumov A; Emami KH
Bioorg Med Chem; 2007 Jan; 15(2):800-14. PubMed ID: 17098432
[TBL] [Abstract][Full Text] [Related]
30. Polo-like kinase 1: a potential therapeutic option in combination with conventional chemotherapy for the management of patients with triple-negative breast cancer.
Maire V; Némati F; Richardson M; Vincent-Salomon A; Tesson B; Rigaill G; Gravier E; Marty-Prouvost B; De Koning L; Lang G; Gentien D; Dumont A; Barillot E; Marangoni E; Decaudin D; Roman-Roman S; Pierré A; Cruzalegui F; Depil S; Tucker GC; Dubois T
Cancer Res; 2013 Jan; 73(2):813-23. PubMed ID: 23144294
[TBL] [Abstract][Full Text] [Related]
31. Plk4 Promotes Cancer Invasion and Metastasis through Arp2/3 Complex Regulation of the Actin Cytoskeleton.
Kazazian K; Go C; Wu H; Brashavitskaya O; Xu R; Dennis JW; Gingras AC; Swallow CJ
Cancer Res; 2017 Jan; 77(2):434-447. PubMed ID: 27872092
[TBL] [Abstract][Full Text] [Related]
32. Expression, adverse prognostic significance and therapeutic small molecule inhibition of Polo-like kinase 1 in multiple myeloma.
Evans RP; Dueck G; Sidhu R; Ghosh S; Toman I; Loree J; Bahlis N; Klimowicz AC; Fung J; Jung M; Lai R; Pilarski LM; Belch AR; Reiman T
Leuk Res; 2011 Dec; 35(12):1637-43. PubMed ID: 21816470
[TBL] [Abstract][Full Text] [Related]
33. Antitumor activity of MLN8054, an orally active small-molecule inhibitor of Aurora A kinase.
Manfredi MG; Ecsedy JA; Meetze KA; Balani SK; Burenkova O; Chen W; Galvin KM; Hoar KM; Huck JJ; LeRoy PJ; Ray ET; Sells TB; Stringer B; Stroud SG; Vos TJ; Weatherhead GS; Wysong DR; Zhang M; Bolen JB; Claiborne CF
Proc Natl Acad Sci U S A; 2007 Mar; 104(10):4106-11. PubMed ID: 17360485
[TBL] [Abstract][Full Text] [Related]
34. SNS-314, a pan-Aurora kinase inhibitor, shows potent anti-tumor activity and dosing flexibility in vivo.
Arbitrario JP; Belmont BJ; Evanchik MJ; Flanagan WM; Fucini RV; Hansen SK; Harris SO; Hashash A; Hoch U; Hogan JN; Howlett AR; Jacobs JW; Lam JW; Ritchie SC; Romanowski MJ; Silverman JA; Stockett DE; Teague JN; Zimmerman KM; Taverna P
Cancer Chemother Pharmacol; 2010 Mar; 65(4):707-17. PubMed ID: 19649632
[TBL] [Abstract][Full Text] [Related]
35. Preclinical characterization of ABT-348, a kinase inhibitor targeting the aurora, vascular endothelial growth factor receptor/platelet-derived growth factor receptor, and Src kinase families.
Glaser KB; Li J; Marcotte PA; Magoc TJ; Guo J; Reuter DR; Tapang P; Wei RQ; Pease LJ; Bui MH; Chen Z; Frey RR; Johnson EF; Osterling DJ; Olson AM; Bouska JJ; Luo Y; Curtin ML; Donawho CK; Michaelides MR; Tse C; Davidsen SK; Albert DH
J Pharmacol Exp Ther; 2012 Dec; 343(3):617-27. PubMed ID: 22935731
[TBL] [Abstract][Full Text] [Related]
36. Inhibition of breast cancer metastases by a novel inhibitor of TGFβ receptor 1.
Fang Y; Chen Y; Yu L; Zheng C; Qi Y; Li Z; Yang Z; Zhang Y; Shi T; Luo J; Liu M
J Natl Cancer Inst; 2013 Jan; 105(1):47-58. PubMed ID: 23178439
[TBL] [Abstract][Full Text] [Related]
37. PLK4: a promising target for cancer therapy.
Zhao Y; Wang X
J Cancer Res Clin Oncol; 2019 Oct; 145(10):2413-2422. PubMed ID: 31492983
[TBL] [Abstract][Full Text] [Related]
38. Inhibition of polo-like kinase 1 leads to the suppression of osteosarcoma cell growth in vitro and in vivo.
Liu X; Choy E; Harmon D; Yang S; Yang C; Mankin H; Hornicek FJ; Duan Z
Anticancer Drugs; 2011 Jun; 22(5):444-53. PubMed ID: 21399492
[TBL] [Abstract][Full Text] [Related]
39. Antitumor activity of edotecarin in breast carcinoma models.
Ciomei M; Croci V; Stellari F; Amboldi N; Giavarini R; Pesenti E
Cancer Chemother Pharmacol; 2007 Jul; 60(2):229-35. PubMed ID: 17089166
[TBL] [Abstract][Full Text] [Related]
40. The PI3K inhibitor GDC-0941 combines with existing clinical regimens for superior activity in multiple myeloma.
Munugalavadla V; Mariathasan S; Slaga D; Du C; Berry L; Del Rosario G; Yan Y; Boe M; Sun L; Friedman LS; Chesi M; Leif Bergsagel P; Ebens A
Oncogene; 2014 Jan; 33(3):316-25. PubMed ID: 23318440
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]